## **Drug Library**

Recommended article: 【Chemoinformatics】 [Material library](https://nate9389.tistory.com/391)

---

**1.** [Overview](#1-overview)

**2.** [Low molecular weight drugs](#2-low-molecular-weight-drugs) 

**3.** [Antibody Drugs](#3-antibody-drugs)

**4.** [Nucleic Acid Treatment](#4-nucleic-acid-treatment)

**5.** [Nanopharmaceuticals](#5-nanopharmaceuticals)

**6.** [Cell therapy](#6-cell-therapy)

**7.** [Radioactive agents](#7-radioactive-agents)

**8.** [Next Generation Drugs](#8-next-generation-drugs)

---

**a.** [Drug class library](https://jb243.github.io/pages/311) 

**b.** [Pharmacology](https://jb243.github.io/pages/2197) 

**c.** [Drug synergy modeling](https://jb243.github.io/pages/2248) 

**d.** [Drug screening technology](https://jb243.github.io/pages/2171) 

---

<br>

## 1. Overview 

⑴ First-Generation Therapies: Chemotherapy, Radiotherapy (Complexity ↓↓)  

> ① Drug Efficacy Assessment: In vitro models (cancer cell lines)  

> ② Mechanism of Action (MoA) / Proof of Concept (PoC): Direct inhibition  

⑵ Second-Generation Therapies: Targeted Therapy (Complexity ↓)  

> ① Drug Efficacy Assessment: Mutation models (PDX, PDC)  

> ② Mechanism of Action (MoA) / Proof of Concept (PoC): Direct inhibition  

> ③ Clinical Biomarkers: Mutations (cfDNA, WES, TES)  

⑶ Third-Generation Therapies: Immunotherapy (Complexity ↑)  

> ① Drug Efficacy Assessment: TMB, TIL, TPS, MSI, Neoantigen  

> ② Mechanism of Action (MoA) / Proof of Concept (PoC): CTL / Macrophages, NK/B/MDSC/Treg, Stroma  

> ③ Clinical Biomarkers: Blood (PBMC, Cytokines), Immune Score  

⑷ **Fourth-Generation Therapies**: Microbiome / Metabolism (Complexity ↑↑)  

> ① Drug Efficacy Assessment: Microbiome, TMB, TIL, TPS, MSI, Neoantigen  

> ② Mechanism of Action (MoA) / Proof of Concept (PoC): CTL / Macrophages, NK/B/MDSC/Treg, Stroma, Microbiome, Metabolites  

> ③ Clinical Biomarkers: Blood (PBMC, Cytokines), Immune Score, Microbiome, Metabolites  

⑸ Recent Drug Trends: Increased drug size, increased fat solubility (clogP)This is contrary to Ripinsky's rule of 5.

⑹ For other information, see [https://www.scinapse.io/](https://www.scinapse.io/) and [https://typeset.io/](https://typeset.io/), which curated billions of papers.

<br>

<br>

## 2. Small Molecule Drugs

 ○ Overview

> ① -nib suffix: In the smallmoleculeinhibitor, abbreviate "inhibit" to -nib

○ 4-aminopyridine (4-AP): A voltage-dependent potassium channel blocker

○ Abiraterone acetate: A CYP17A1 inhibitor. Reduces PSA.

○ Adagarasib: KRAS G<sup>12C</sup> inhibitor

○ Afatinib: EGFR inhibitor 

○ Afuresertib: pan-AKT inhibitor 

○ Alexidine: Targeting DDR2

○ AMD3100: CXCR4 inhibitor

○ AMPA: An agonist for AMPA type glutamate receptor

○ Anifrolumab

> ① IFNAR1 antagonist

> ② FDA approval for SLE (Systemic Lupus erythematosus) treatment in 2021

○ AP5: A competitive antagonist for NMDA receptors

○ Asras tablet

> ① circular purification of microsulfur nuclei

> ② Nonsteroidal antipyretic, anti-inflammatory (inflammatory relief), painkillers

> ③ Store in airtight container at room temperature (1-30℃)

○ AVL-292: BTK inhibitor

○ AZ138: Eg5 inhibitor

○ Azacytidine: DNA methylation inhibitor

○ AZD7762: CHEK1/2 inhibitor

○ BAY73-4506: Blockade of RAF

○ Benfluorex: Withdrawn due to cardiovascular side effects

○ Bicuculline methiodide: GABA<sub>A</sub> receptor antagonist

○ Bleomycin: Induces lung injury.

○ Bosutinib: BCR-ABL inhibitor

○ cAMP phosphodiesterase: cAMP inhibitor

○ Canertinib: EGFR/HER inhibitor

○ Cannabanine

> ① A large amount is present in the seeds of Canavalia eniformis.

> ② Substances very similar in structure to the amino acid arginine.

> ③ Non-protein amino acids that are not expressed in living proteins, and arginine-filled enzymes in herbivores cannot distinguish arginine from cannabanine, producing tRNA linked to cannabanine instead of arginine.

> ④ Canabanin is inserted into protein instead of arginine, resulting in the deformation of the tertiary structure of the protein, which makes it impossible to function normally, and the larvae of herbivores who ate it die.

○ Capillin: fungicide

○ (R)-(-)-carvone: spearmint oil

○ (S)-(+)-carvone: caraway seed oil

○ CGM097: Targeting MDM2 mutant form specifically 

○ CGP55845: GABA<sub>B</sub> receptor blocker

○ CHIR99021: GSK3inhibitor, WNT activator

○ Ciliobrevin D: inhibitor of degranulation of NK cells

○ Cinnamaldehyde: cinnamon flavoring

○ Cisplatin: FAP inhibitor

○ CNQX: A competitive antagonist for non-NMDA receptor

○ CNX-774: BTK inhibitor

○ Crizotinib

> ① A receptor tyrosine kinase inhibitor and ROS1 inhibitor primarily used for NSCLC (Non-Small Cell Lung Cancer).

> ② The drug was approved by the FDA in 2021 and is also used for colorectal cancer. 

○ Cyclosporine A: widely used in dry eye syndrome treatment 

○ Dasatinib: BCR-ABL inhibitor

○ Decitabine: DNMT inhibitor (DNA methylation inhibitor)

○ Demecolcine: Microtubule destabilizing agent

○ Deoxycholic acid: Component of subsequent fat removal injection. trademark name is Kybella

○ Diethylstilbestrol (DES)

> ① drug for preventing pregnant failure prescribed between 1938 and 1971

> ② Estrogen simulation causes abnormalities in fetal uterine development: 24% of daughters born are infertile

> ③ Synthetic female hormone without steroid backbone

> ④ Prohibition of the use of backtracking research results by 20,000 women

○ Diazinon: insect repellent

○ DM1: microtubule inhibitor 

○ DNQX: AMPA receptor antagonist 

○ Dopa: A treatment for Parkinson’s disease, is effective in its L-form only. 

○ Doxycyclin: be used as an anticancer drug

○ enasidenib (Celgene) : mIDH inhibitor

○ Enediyne: anti-cancer drug

○ Erlotinib (Tarceva): EGFR inhibitor

○ Esomeprazole: proton pump inhibitor, digestive medicine

○ Finerenone

> ① NR3C2 antagonist

> ② FDA approval for CKD (chronic kidney disease) treatment in 2021

○ Gabazine: GABA<sub>A</sub> receptor antagonist

○ Galunisertib (LY21577299) : TGF-βR1 inhibitor

○ Gardine tablet

> ① lanitidine hydrochloride H<sup>2</sup> blockers and gastric acid secretion inhibitors

> ② Prevention and treatment for gastric ulcer, duodenal ulcer, gastroesophageal reflux disease

○ Gefitinib (Iressa): EGFR inhibitor 

○ Gemcitabine

> ① first line drug of pancreatic cancer

> ② pyrimidine antimetabolite

○ GPX4 inhibitor: ML210, RSL3 

○ GSK690693: blockade of AKT

○ 4-hydroxybutanoic acid: a so-called mulberry drug

○ Ibotenic acid

> ① Compounds found in clown mushrooms and devil clown mushrooms

> ② If you eat a lot, you will have hallucinations.

○ Ibrutinib 

> ① It targets Bruton's tyrosine kinase (BTK) irreversibly.

> ② FDA approved for mantle cell lymphoma, chronic lymphocytic leukemia, and multiple hematological malignancy.

○ Ichthyothereol: convulsant

○ (-)-iridomyrmecin: compounds released when ants try to protect themselves from predators

○ Ispinesib: Specifically inhibits Kinesin spindle protein (KSP) 

○ ITX-5061: Antagonist of SCARB1 

○ ivosidenib (Agio): mIDH inhibitor

○ IWR-1-endo (Calbiochem): Wnt inhibitor 

○ JQ1: BRD2, BRD3, BRD4, BRDT inhibitor 

○ Kainic acid: An agonist for both kainate and AMPA glutamate receptors

○ Kyn: An ionotropic glutamate receptor antagonist 

○ Lobeglitazone (Lobe)

> ① antiatherogenic drug

> ② promotes cholesterol efflux (through PPARγ activation & LXRα, ABCA1, and ABCG1 dependent pathways)

○ Losartan: angiotensin inhibitor

○ Loxonin: Painkillers

○ LY-294002: Classical PI3K inhibitor

○ Met-enkephalin: Opioid receptor agonist 

○ (S)-methamphetamine:illegal // (R)-methamphetamine:legal

○ Mivobulin isethionate: Colchicine analog. Also a microtubule targeting agent.

○ MK801: A NMDA receptor open-channel blocker. The non-competitive NMDA receptor antagonist 

○ MMAE(monomethyl auristatin E): Tubulin polymerization inhibitor

○ Nandrolone: anabolic steroids illegally used by athletes to strengthen their muscles

○ NEM(N-ethylmaleimide): chemical that binds to myosin and inhibits its function

○ Niclosamide: anthelminthic drug

○ Nilotinib: BCR-ABL inhibitor

○ NMDA: An agonist for NMDA receptor

○ Ogumentin tablet

> ① white or nearly white oval

> ② Penicillin antibiotic used for bacterial infections

> ③ Store in airtight container (moisturizing packaging) at 1-25°C

> ④ Be careful of constipation and dizziness

○ Olaparib: PARP inhibitor 

○ Osimertinib (Tagrisso): EGFR inhibitor

○ Palbociclib

> ○ An FDA-approved treatment for breast cancer.

> ○ It selectively inhibits cyclin-dependent kinases CDK4 and CDK6.

○ Panobinostat: pan‐HDAC inhibitor

○ PD0325901: MEK inhibitor

○ PD173074: specific VEGFR inhibitor

○ PF7845-yne: Fatty acid amide hydrolase (FAAH) inhibitor 

○ Phalloidin: Targeting actin filament

○ RGFP966: Targeting GATA2

○ Ricin: ribosome-inactivating protein created by Ricinus communis

○ S1 nuclease: Hydrolyze all of the nucleic acid endotransferase, single-stranded DNA, or RNA isolated from Aspergillus aurizae

○ SB431542 (Stemgent): TGF-β inhibitor 

○ Silmitasertib(CX-4945): Kinase CK2 inhibitor 

○ Sotorasib: FDA approval for KRAS<sup>G12C</sup> non-small-cell lung canceller

○ SP600125: blockade of JNK

○ SR95531: GABA<sub>A</sub> receptor blocker 

○ Talabostat: FAP inhibitor

○ Tazemetostat: EZH2 inhibitor

○ TBOA

> ○ A competitive antagonist for glutamate transporters

> ○  Haas at least one hydrophobic benzyl group larger than glutamate

> ○ TBOA mimics glutamate in potentiating GABA<sub>A</sub>-receptor-mediated responses

○ Tepoxalin: It specifically kills cells with high ABCB1 expression.

○ Tirofiban: Glycoprotein IIb/IIIa receptor inhibitor.

○ Toxane: microtubule toxin

○ Tramol tablet

> ① white circular tablet

> ② Lower fever and reduce pain as antipyretic drugs

> ③ Stored at room temperature (1-30℃) in an airtight container

○ Transgelin: smooth muscle marker

○ Trifluralin B: non-selective herbicide.

○ TTX: A voltage-dependent sodium channel blocker

○ Unifectan capsule

> ① upper green and lower yellow capsules containing white powder

> ② Easy discharge of sputum with sputum solubilizer

> ③ Store in airtight container at room temperature (1-30℃)

> ④ Beware of dizziness

○ Vanadium: It specifically kills cells with high SLC26A2 expression.

○ Vanillin: Vanilla flavoring.

○ Venetoclax: BCL-2 inhibitor 

○ Vismodegib: SHH inhibitor

○ Vorinostat: α histone deacetylase inhibitor.

○ VS-4718: FAK inhibitor

○ WAY100,635: 5HT1A receptor antagonist

○ Wortmannin: PI3K inhibitor 

○ Y-27632: ROCK inhibitor

<br>

<br>

## 3. Antibody Drugs 

⑴ Overview

> ① Since antibodies themselves are large, only a part of them are generally used as drugs.

>> ○ VH

>> ○ Fab

>> ○ scFv

>> ○ diabody

>> ○ scFv-Fc

>> ○ scFv-CH

>> ○ scFab

>> ○ scFv-zipper

> ② Humanization should be performed to prevent antibody drugs from triggering immune responses in the human body.

>> ○ Types of humanization: mab means monoclonal anibody

>>> ○ -omab: murine (0% human).ability to act as an antigen in humans

>>> ○ -ximab: chimeric (65% human)

>>> ○ -zumab: humanized (＞ 90% human)

>>> ○ -umab: fully human (100% human)

>> ○ humanization method

>> ○ phage display

>> ○ transgenic mouse

> ③ Antibody drugs last long in the blood, so you can prescribe them from time to time.

⑵ General Antibody Drugs: be labeled as "antigen:antibody"

> ○ CAIX: cG250

> ○ CD20: rituximab, ibritumomab tiuxetan, tositumomab

> ○ CD3: CD8 T cell activator

> ○ CD3/CD28: CD4 T cell activator

> ○ CD30: brentuximab vedotin

> ○ CD33: gemtuzumab ozogamicin

> ○ CD4/8: T cell depletion

> ○ CD52: alemtuzumab

> ○ CEA: labetuzumab

> ○ CTLA4: ipilimumab

> ○ EGFR: cetuximab, panitumumab, nimotuzumab, 806

> ○ EpCAM: IGN101, adecatumumab

> ○ EPHA3: KB004, IIIA4

> ○ ERBB2: trastuzumab, pertuzumab

>> ○ trastuzumabThis glioblastoma is actually the only drug.

>> ○ 98% of small molecule drug is suppressed by close connection of brain capillaries.

> ○ ERBB3: MM-121

> ○ FAP: sibrotuzumab, F19

> ○ folate binding protein: MOv18, MORAb-003 (farletuzumab)

> ○ FRα (folate receptor α): mirvetuximab soravtansine with DM4

> ○ fusion protein of RSV : palivizumab

> ○ ganglioside (e.g., GD2, GD3, GM2): 3F8, ch14.18, KW-2871

> ○ gpA33: huA33

> ○ GP IIb/IIIa: abciximab

> ○ HER2: margetuximab (monoclonal antibody)

> ○ HER2: trastuzumab emtansine with DM1

> ○ IGF1R: AVE1642, IMC-A12, MK-0646, R1507, CP751871

> ○ IL-4R: Dupilumab, a treatment for atopic dermatitis, binds to the target called IL-4R and inhibits the secretion of IL-4R.

> ○ IL-6R: tocilizumab is anti-IL-6R humanized monoclonal antibody

> ○ integrin α5β1: volociximab

> ○ integrin αVβ3: etaracizumab

> ○ Leγ: hu3S193, IgN311

> ○ MET: AMG102, METMAB, SCH900105

> ○ microtubule: enfortumab vedotin 

> ○ mucin: pemtumomab, oregovomab

> ○ PD1: XMT-2056

> ○ PD1: nivolumab (first approval in 2014 for melanoma)

> ○ PD1: pembrolizumab

> ○ PD-L1: atezolizumab (monoclonal antibody)

> ○ PSMA: J591

> ○ RANKL: denosumab

> ○ TAG-72: CC49 (minretumomab)

> ○ tenascin: 81C6

> ○ topoisomerase I: trastuzumab deruxtecan 

> ○ TRAILR1: mapatumumab (HGS-ETR1)

> ○ TRAILR2: HGS-ETR2, CS-1008

> ○ TROP2: sacituzumab govitecan with SN-38

> ○ VEGF: ranibizumab, aflibercept, bevacizumab

> ○ VEGFR: sunitinib, pazopanib, axitinib, IM2C6, CDP791

<br>

<img width="946" height="654" alt="스크린샷 2025-10-09 오후 1 49 51" src="https://github.com/user-attachments/assets/c7e27ac0-4fb5-472a-9322-a0821a0fed49" />

**Table 1.** Clinically approved antibody–drug conjugates

<br>

⑶ Bispecific antibody 

⑷ TCE(T cell engager) 

> ○ Blinatumomab: Bispecific T cell engager

> ○ Glofitamab: Bispecific T cell engager

> ○ Mosunetuzumab: Bispecific T cell engager

> ○ Tarlatamab: Used for the treatment of small cell lung cancer, is currently the only TCE that has achieved clinical proof of concept in solid tumors.

> ○ Teclistamab: Bispecific T cell engager

<br>

<br>

## 4. Nucleic Acid Treatment 

⑴ **Type 1.** siRNA

⑵ **Type 2.** Nucleic Acid Nanopharmaceuticals: DNA aptamer, DNA origami, etc.

<br>

<br>

## 5. Nanopharmaceuticals 

⑴ Overview

> ① Advantages: Design is possible. Various functions can be given through surface modification.ease of introduction of concomitant drugs

> ② Disadvantages: Difficulty in mass production.It can break down in vivo and cause toxicity or side effects

⑵ **Type 1.** Liposome

⑶ **Type 2.** IONP (iron oxide nanoparticle)

⑷ **Type 3.** MSNP (mesoporous silica nanoparticle)

⑸ **Type 4.** Nucleic acid nanopharmaceuticals: DNA aptamer, DNA orgami, etc.

⑹ **Type 5.** LNP: In vivo unstable siRNA, mRNA, etc. delivered to target

> ① ALC-0315 (Pfizer/BioNTech)

> ② SM-102 (Moderna)

> ③ ALC-0159 (Pfizer/BioNTech)

> ④ PEG-DMG (Moderna)

<br>

<br>

## 6. Cell Therapy 

⑴ Overview

> ① Advantages

>> ○ Design is possible.

>> ○ It can utilize cell-specific functions such as crossing BBB or supplementing defective tissues.

> ② Disadvantages

>> ○ low yield and low repeatability

>> ○ Cells that are therapeutic must survive

>> ○ The high cost

>> ○ It can also form tumors.

> ③ Cell therapy works well for blood cancer, but not for solid cancer.

⑵ **Type 1.** CAR(chimeric antigen receptor)-T cell therapy

> ① 1<sup>st</sup>. Extract T cell from patient's blood

> ② 2<sup>nd</sup>. Inject the inactive virus into the T cell to express an engineered receptor.

> ③ 3<sup>rd</sup>. GROWTH TO MILLIONS OF CELL

> ④ 4<sup>th</sup>. Injection into the patient's body → Cancer treatment

> ⑤ Blood cancer is treated well, but solid cancer is not treated well.

>> ○ Reason: Unlike blood cancer, tumor microenvironment of solid cancer reduces CAR-T activity.

> ⑥ Currently, there are five CAR-T FDA approved drugs.

>> ○ Tisagenlecleucel (Kymriah): 2017

>> ○ Axicabtagene ciloleucel (Yescarta): 2017

>> ○ Brexucabtagene autoleucel (Tecartus): 2020

>> ○ Lisocabtagene maraleucel (Breyanzi): 2021

>> ○ Iidecabtagene vicleucel (Abecma): 2021

⑶ **Type 2.** Sipuleucel-T

> ① Examples of Cancer vacine for treatment

> ② 1<sup>st</sup>. Extract antigen-presenting cells (APCs) from patients

> ③ 2<sup>nd</sup>. Exposurend of antigen to antigen-presenting cells in vitro

> ④ 3<sup>rd</sup>. Infuse the learned antigen-presenting cells back into the patient

> ⑤ Used to treat prostate cancer

> ⑥ Advantages of being able to provide one-on-one customized treatment

⑷ **Type 3.** Stem cell therapy

⑸ **Type 4.** Microbial treatment

<br>

<br>

## 7. Radioactive Drugs 

⑴ <sup>18</sup>F-FDG has fewer side effects: it uses fewer substances.

<br>

<br>

## 8. Next Generation Drugs

⑴ small molecule

> ① small molecule

> ② PROTAC

> ③ zirconium cyclosilicate

⑵ antibody therapeutic

> ① monoclonal antibody

> ② antibody drug conjugate

> ③ bispecific antibody

> ④ fragment antibody

⑶ peptide or protein therapeutic

> ① therapeutic protein

> ② bicyclic peptide

> ③ anticalin® protein

⑷ nucleotide-based therapeutic

> ① antisense oligonucleotide

> ② oligonucleotide conjugate

> ③ small interfering RNA

> ④ mRNA

> ⑤ therapeutic gene editing

⑸ cell-based therapeutic

⑹ IVEB(in vivo expressed biologics)

<br>

---

_Input: 2022.04.24 14:19_
